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Abstract
Purpose—Breast cancer is a heterogeneous disease, with at least five intrinsic subtypes defined
by molecular characteristics. Tumors that express the estrogen receptor (ER+) have better
outcomes than ER− tumors, due in part to the success of hormonal therapies that target ER+
tumors. The incidence of ER− breast cancer, and the subset of ER− cancers that are basal-like, is
about twice as high among African American (AA) women as among U.S. women of European
descent (EA). This disparity appears to explain, in part, the disproportionately high mortality from
breast cancer that occurs in AA women. Epidemiologic research on breast cancer in AA women
lags behind research in EA women. Here, we review differences in the etiology of breast cancer
subtypes among AA women and describe a new consortium of ongoing studies of breast cancer in
AA women.
Methods—We combined samples and data from four large epidemiologic studies of breast
cancer in AA women, two cohort and two case-control, creating the AMBER consortium. Tumor
tissue is obtained and stored in tissue microarrays, with assays of molecular markers carried out at
a pathology core. Genotyping, carried out centrally, includes a whole exome SNP array and over
180,000 custom SNPs for fine-mapping of GWAS loci and candidate pathways.
Results—To date, questionnaire data from 5,739 breast cancer cases and 14,273 controls have
been harmonized. Genotyping of the first 3,200 cases and 3,700 controls is underway, with a total
of 6,000 each expected by the end of the study period.
Conclusions—The new consortium will likely have sufficient statistical power to assess
potential risk factors, both genetic and non-genetic in relation to specific subtypes of breast cancer
in AA women.
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INTRODUCTION
Breast cancer is a heterogeneous disease.[1, 2] Assessing etiologic factors for all breast
cancers combined may result in weak or null findings that obscure important risk
relationships for specific disease subgroups. The earliest and most frequently used molecular
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classification of breast cancer is by hormone receptor status; women with tumors that
express the estrogen receptor (ER+) have better outcomes than those with ER− tumors, due
in part to the success of hormonal therapies that target ER+ tumors.[3–5] Presence or
absence of progesterone receptors is also a prognostic factor.[6]
The incidence of ER/PR positive and negative tumors varies by race in the United States.[7–
11] Non-Hispanic white women have the highest rates of ER+ tumors, while non-Hispanic
black women have the highest rates of ER− tumors. Findings from studies of all breast
cancers have been useful for understanding risk of breast cancer in European ancestry (EA)
women because about 80–85% of cancers in EA women are ER+. By contrast, only 60–65%
of breast cancers in women of African ancestry (AA) are ER+.[11] Breast cancer mortality
is higher in AA women than in EA women at every age, and the mortality disparity is not
fully explained by factors related to access to optimal and timely screening and care.[12–14]
The higher incidence of ER− tumors likely plays a role in these survival disparities. A better
understanding of the etiology of ER− breast cancer is essential for reducing breast cancer
incidence and mortality in AA women.
While the most common classification of breast tumors for etiologic research has been by
ER and PR status, additional markers have been identified as having prognostic value and
are increasingly being assayed at the time of diagnosis. Five “intrinsic” subtypes of breast
cancer that exhibit different clinical outcomes and express different therapeutic targets have
been identified and validated across multiple datasets and study populations.[1, 2, 15–19] A
validated panel of immunohistochemical (IHC) markers has been developed to identify the
intrinsic subtypes: Luminal A (ER+ and/or PR+ and HER2−), Luminal B (ER+ and/or PR+
and either HER2+ or Ki-67+), HER2+/ER− (ER− PR− HER2+), Basal-like (ER− PR−
HER2−, CK5/6+ and/or HER1+) and Unclassified (ER− PR− HER2− CK5/6− HER1−).[20–
22] Notably, the intrinsic subtypes distinguish between two subtypes of triple negative
breast cancer: the poor prognosis “basal-like” subtype that exhibits high proliferation rates
and expression of cytokeratins 5/6, HER1/EGFR and other potential therapeutic targets, and
the “Unclassified” group that shows more favorable prognosis and lacks expression of the
basal-like markers.[22] As demonstrated in data from the Carolina Breast Cancer Study
(CBCS), the intrinsic subtypes exhibit differing clinical profiles that justify consideration as
separate disease entities.[20] Reports from CBCS[23] and others[24] suggest that the
intrinsic subtypes may also have different etiologic patterns, but the data are not definitive.
We hypothesize that differential distributions of reproductive and other lifestyle factors may
play a role in the higher prevalence of ER− tumors in AA women. Rare and common genetic
variants that infer susceptibility may also be important, either alone or in concert with
exposures. Here we review differences in the etiology of breast cancer subtypes among AA
women and describe a new consortium designed to investigate risk factors for distinct breast
cancer subtypes among AA women.
FACTORS THAT MAY EXPLAIN DIFFERENCES IN SUBTYPES
Reproductive factors
Several studies[23, 25–28] have investigated risk factors for breast cancer in AA women,
but each had limited statistical power for examining risk factors for specific subtypes. The
CBCS,[23] the Black Women’s Health Study (BWHS),[29] and a growing number of other
studies have provided intriguing data showing that parity is associated with a reduced risk of
ER+ breast cancer but increases risk of ER− and basal-like breast cancer.[30–32]
Importantly, breastfeeding appears to ameliorate the increased risk or ER− and basal-like
breast cancer associated with parity[23, 29] New research on pregnancy-associated breast
cancer suggests that immune/inflammation pathways may mediate the relationship between
Palmer et al. Page 2













parity, lactation, and breast cancer.[33] There is also evidence that oral contraceptive use is a
stronger risk factor for ER− than ER+ breast cancer.[34, 35]
Reproductive factors differ in prevalence between AA and EA women. AA women have an
earlier age at menarche, are more likely to have their babies at a young age, and are less
likely to breastfeed their babies.[36] Taken together, these findings raise the provocative
hypothesis that the higher incidence of ER−, triple negative, and basal-like breast cancer in
AA women may be explained, in part, by childbearing and lactation patterns. Confirmation
of these findings in a statistically powerful study of breast cancer subtypes could have
important public health implications. The results might provide the impetus for intensified
efforts to encourage breastfeeding and facilitate it in the workplace, not only for the health
of babies, but also to reduce risk of the more lethal forms of breast cancer.
Obesity and physical activity
An epidemic of obesity has broadly affected the American population, particularly AA
women,[37, 38] of whom more than half are obese (body mass index (BMI) ≥30kg/m2).
Abdominal obesity, often measured by waist circumference or waist to hip ratio (WHR),[39]
has also increased greatly; more than 70% of AA women ages 20–79 had a waist
circumference of 88 cm or greater in 1999–2000,[40] a level of abdominal obesity
associated with severe adverse health consequences.[41] While overall obesity is associated
with many adverse health outcomes,[42, 43] the health effects of abdominal obesity may be
even worse, reflecting metabolic derangements (e.g., dyslipidemia, glucose intolerance)
associated with abdominal fat.[39, 42–49] In the majority of studies conducted in EA
women, high BMI is associated with reduced risk of premenopausal breast cancer and
increased risk of postmenopausal breast cancer.[25, 50–52] Abdominal adiposity is
associated with increased risk of both premenopausal and postmenopausal breast cancer.[39,
53] The association of overall obesity with increased risk of postmenopausal breast cancer
has been most consistently noted for ER+/PR+ tumors.[54–56] Results on other subtypes are
variable. In the CBCS, high BMI was not associated with increased risk of luminal A tumors
in postmenopausal women.[23] However, among both pre- and postmenopausal women,
higher WHR was strongly associated with increased risk of basal-like tumors, independent
of BMI, with a weaker association for luminal A tumors.
Evidence for a BMI association in AA women is sparse, with inconsistent results from early
case-control studies.[27, 50, 57–59] The Women’s CARE study reported an inverse
association of BMI at age 18 with premenopausal ER−/PR− breast cancer and a positive
association of recent BMI with postmenopausal ER+/PR+ breast cancer.[60] In the BWHS,
high BMI at age 18 was associated with reduced risk of both pre- and postmenopausal breast
cancer, and current BMI was inversely associated with premenopausal cancer.[25] There
was suggestive evidence of a positive association of high BMI with ER+/PR+ tumors. The
CBCS found no association of BMI with postmenopausal breast cancer and positive
associations of high WHR with risk of both pre- and postmenopausal breast cancer.[50]
CBCS results on intrinsic subtypes (described above) were not presented by race. Recently,
the Women’s Circle of Health Study (WCHS) observed significant inverse associations of
high BMI with ER−/PR− breast cancer among postmenopausal women. Similar to the
CBCS, higher waist circumference was associated with increased risk of premenopausal
breast cancer in the WCHS after adjustment for BMI.
Obesity may affect breast cancer risk through several different and overlapping pathways
involving changes in circulating cytokine and adipokine levels, insulin resistance,
circulating insulin levels, sex hormones, and growth factors.[61, 62] Because AA women
are more likely to be obese and to have high WHR, one would predict that there would be
strong positive associations between obesity and the aggressive breast tumors seen more
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commonly in AA women. This does not appear to be the case, however, and there is clearly
a need for further epidemiologic and mechanistic research.
Based on the results of numerous epidemiologic investigations of overall breast cancer, the
World Cancer Research Fund/American Institute for Cancer Research has judged it probable
that exercise reduces risk of postmenopausal breast cancer and considers evidence for
premenopausal cancer to be limited.[63] Some studies suggest that an inverse association of
exercise with breast cancer risk may be stronger among leaner women;[64–67] if so, this
would be particularly relevant to AA women because of their higher prevalence of obesity.
Data on exercise and subtypes of breast cancer are limited: a few studies found a stronger
inverse association with ER− cancer than with ER+ cancer[66, 68, 69] while others found no
difference.[67, 70, 71] To date, there are no published results on subtypes specifically from
AA women.
Evolutionary factors - Inflammation and vitamin D
Higher proportion of African ancestry, as estimated through the use of Ancestry-Informative
Markers (AIMs), a set of polymorphic markers that vary between populations with different
geographic origins, has been shown to be associated with ER− and triple negative breast
cancer.[72, 73] The reasons for this association are unclear. It may be that certain genetic
variants, more prevalent among Africans, confer susceptibility to ER −, triple negative,
basal-like breast cancers, as discussed below. It is also possible that other factors associated
with evolution over millennia in Africa could play an etiologic role. For example, higher
melanin content and dark skin pigmentation are considered to be the ancestral skin color,
with migration to northern hemispheres resulting in lighter skin, perhaps for better
absorption of ultraviolet light for the synthesis of vitamin D. In North America, vitamin D
deficiency (≤15 ng/ml) is almost 10 times higher in AA than in EA women,[74] with the
prevalence of severe vitamin D deficiency among AAs at 29% in 2001–2004.[75] In the
WCHS, severe vitamin D deficiency (< 10 ng/ml) was present in 34% of AAs, but only 6%
of EAs.[76] Furthermore, higher proportion of African ancestry, measured by AIMS, was
associated with lowest levels of serum 25(OH)D.[76] Thus, it is possible that high melanin
content allows for adequate sun absorption and vitamin D synthesis in a rural environment
in sub-Saharan African but results in low serum 25(OH)D in northern regions and in
societies where most time is spent indoors.
In regard to the relationship between levels of vitamin D and breast cancer risk, a recent
meta-analysis of data from nine prospective studies concluded that higher levels of
25(OH)D were associated with lower risk of breast cancer risk in postmenopausal, but not
premenopausal women.[77] However, as is the case for reproductive risk factors,
associations may vary according to breast cancer subtypes. In a study of premenopausal EA
women, we found that levels of 25(OH)D were highest among controls, and lowest among
women with triple negative breast cancer, particularly in comparison to those with luminal
A subtype.[78] Lower levels of 25(OH)D were observed in women with triple negative
breast cancer in two other studies,[79, 80] whereas some studies that examined 25(OH)D
levels according to ER and PR status without considering HER2 status did not find such
associations.[81–83] These results, taken together, suggest that low serum 25(OH)D in AAs
could be associated with more aggressive breast cancers.
There may have also been evolutionary selection on the innate and adaptive immune
systems for more robust inflammatory responses to withstand endemic infectious disease. A
less restrained immune response, while beneficial for resisting and surviving infectious
diseases, may play a role in malignant transformation and cancer risk in later life. Indeed,
biomarkers of low grade chronic inflammation have been associated with greater risk of
cancer, higher tumor grade, and poorer cancer survival,[84–87] and SNPs and levels of
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several pro-inflammatory cytokines related to innate immunity have been associated with
breast cancer risk,[88] stage, and progression.[89] SNPs associated with increased levels of
pro-inflammatory cytokines, such as IL1, IL2, IL6, and IL18, are more common in AA than
in EA women.[90] In addition to differences by ancestry in non-specific innate immune
system pathways, there is natural selection in sub-Saharan Africa for genotypes by specific
families of infectious agents such as protozoa and helminths, with a shift to TH2 immunity
for exposure to helminths. Endemic malarial parasites have dominated the infectious
landscape in sub-Saharan Africa for millennia, with a profound influence on the selection of
genetic variation.[91] Thus, specific genetic profiles that confer resistance in Africans have
evolved, such as the β-globin locus and other hemoglobin genes, G6PD, the Duffy antigen
gene,[92] and loss of T cell function.[93] Although data are lacking from large prospective
epidemiological studies on immune factors and breast cancer risk, in the WCHS, SNPs in
both innate and adaptive immune response pathways were differentially distributed by race,
with associations noted between several SNPs in these immune pathways and breast cancer
risk.[94, 95] In mice, specific malaria-driven genetic changes such as loss of the Duffy
antigen receptor result in higher serum chemokine levels and increased inflammatory milieu,
predisposing to the development of more aggressive prostate tumors.[96] A similar
mechanism could exist for human breast cancer; recently, using serum obtained prior to
surgery from women with incident breast cancer, Hong and colleagues showed that levels of
IL-5, a Th2 cytokine, were higher in women with ER− than in ER+ tumors and that women
with highest ratios of TH1 cytokines to IL-5 were least likely to have ER− or triple negative
breast cancer.[97]
Genomics and breast cancer subtypes in AA women
To date, there have been only two genome wide association studies (GWAS) of breast
cancer in women of African ancestry, one with approximately 3,000 cases (AABC)[98, 99]
and the other with almost 2,000 cases (ROOT).[100] No new loci have been identified as
associated with breast cancer risk at a genome-wide significance level in either GWAS or in
a meta-analysis of both scans. By comparison, over 70 breast cancer loci have been
identified in GWAS data from EA populations.[101, 102] There have been several reports of
transferability of European/Asian GWAS index SNPs to African ancestry populations, with
replication of only a few of the index SNPs.[72, 98, 103–105]
Only the AABC and BWHS have reported genetic results according to ER and PR status.
[72, 98] A meta-analysis of AABC data with data from a GWAS of triple-negative breast
cancer in EA women identified a new locus on the TERT gene associated with ER− breast
cancer.[106] A SNP in the 19p13 region that was associated with ER− and triple-negative
breast cancer in EA was replicated in the BWHS for both subtypes.[72] Global percent
African vs. European genetic ancestry in AA women was associated with subtype in the
BWHS.[72] Relative to women with ER+/PR+ breast cancer, women with ER−/PR− cancer
were twice as likely to be in the highest quintile of African ancestry and women with triple
negative breast cancer were three times as likely to be in that quintile. A similar association
of global ancestry with ER−/PR− relative to ER+/PR+ cancer was observed in an admixture
scan of AA breast cancer that included cases and controls from CBCS, WCHS, Multiethnic
Cohort (MEC) and other studies.[73] These findings suggest that there may be African
ancestry specific variants that increase susceptibility to specific subtypes of cancer.
However, studies to date have been underpowered to detect even common variants that may
be African ancestry specific.
THE AMBER CONSORTIUM
Because of the critical gaps in knowledge discussed above, it is essential that more research
be directed toward understanding the causes of ER− and basal-like breast cancer in AA
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women. It is clear that such research will be effective only if studies with appreciable
numbers of AA women combine their data for increased statistical power. To this end, the
authors initiated collaborations among four of the largest ongoing studies of breast cancer in
AA women: two case-control studies (CBCS and WCHS) and two prospective cohort
studies (BWHS and MEC). The collaboration, African American Breast Cancer
Epidemiology and Risk (AMBER), is designed to pool existing data, continue accrual of
new cases with periodic additions to the pooled data set, and carry out subtyping assays of
tumor tissue samples, genotyping assays of DNA samples, and statistical analyses of
questionnaire data within dedicated cores so that the same methods are applied across
studies. We expect that by study end, AMBER will include more than 6,000 AA women
with breast cancer and more than 6,000 AA controls for evaluation of breast cancer risk
factors by subtype. The contributing studies are described briefly below.
The Carolina Breast Cancer Study (CBCS) is a North Carolina population-based case
control study of breast cancer, conducted in three phases.[107, 108] The current study phase,
phase 3 (years 2008–2014), includes women resident in 44 counties. CBCS phases 1 and 2
were conducted in 24 counties. Breast cancer cases are identified using Rapid Case
Ascertainment in cooperation with the NC Central Cancer Registry. Controls were identified
for phases 1 and 2 only (1993–1996 and 1996–2001), using Division of Motor Vehicles lists
for women under age 65 and Health Care Financing Administration lists for women 65 and
older. Randomized recruitment was used to oversample AA women and women under age
50. The age range of study participants is 20 to 74. Procedures for recruiting and enrolling
study participants were approved by the Institutional Review Board of the UNC School of
Medicine and informed consent was obtained for each participant. Cases of invasive breast
cancer were enrolled in all three phases and cases of in-situ breast cancer were enrolled
during Phase 2 only; all cases of in-situ breast cancer were eligible, with no over-sampling
according to age or race. Controls enrolled in phases 1 and 2 were frequency matched to
cases based upon age (+/− 5 years) and race. Rapid Case Ascertainment has resulted in an
average time interval of six months between date of diagnosis and date of interview. In-
depth interviews are conducted by study nurses in participants' homes to obtain information
on family history and other risk factors for breast cancer, including reproductive history,
physical activity, breast cancer screening and access to health care and other lifestyle
factors. The interviewers measure height, weight, and waist circumference, and obtain blood
or mouth rinse samples. During Phases 1 and 2, 787 AA invasive cases and 718 AA controls
and 107 AA in situ cases and 70 AA controls were enrolled. Overall response rates (product
of contact and cooperation rates) were 74% for AA cases and 54% for AA controls. To date,
the response rate for Phase 3 for AA cases is 70.5%.
Blood samples were collected into ACD-anticoagulated tubes. During phases 1 and 2, 86%
of AA cases and 86% of AA controls provided blood samples that yielded sufficient DNA
and plasma for laboratory analyses. There were no statistically significant differences
between persons with and without DNA according to age, menopausal status, family history
of breast cancer, smoking, hormone use, age at menarche, parity or other breast cancer risk
factors. Stage at diagnosis did not differ significantly between cases who gave DNA and
those who did not. In phase 3, blood samples have been obtained from 58% of cases; 39% of
cases have provided mouth rinse or saliva samples. Thus, viable DNA samples have been
obtained from 97% of enrolled participants in phase 3.
The Women’s Circle of Health Study (WCHS) is a multi-site case–control study in New
York City (NYC) and New Jersey (NJ) aimed at evaluating risk factors for early and
aggressive breast cancer in women of AA and EA ancestry.[109, 110] Cases are women
with primary, histologically confirmed invasive breast cancer or ductal carcinoma in situ,
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ages 20–75 years. Controls are frequency matched on age and race. Both cases and controls
must have no previous history of cancer other than non-melanoma skin cancer.
Recruitment in NYC took place between January 2002 and December 2008 and involved
hospital-based ascertainment of cases, while controls were identified through random digit
dialling (RDD), frequency matching to telephone prefixes of cases. The sampling frame was
designed so that cells categorized by age were filled in similar proportions to those of the
cases. Recruitment at the NJ site started in March 2006 and is ongoing. Phase I of the study
ended in April 2012 and covered seven counties in NJ (Bergen, Essex, Hudson, Mercer,
Middlesex, Passaic, and Union). WCHS2 includes two additional counties for a total of nine
counties. Cases in NJ were identified from 2006 to 2012 by the NJ State Cancer Registry
using rapid case ascertainment. Controls were initially recruited though RDD (2006 to 2010)
and later through community-based efforts (2009–2012). In-person interviews ascertained
data on established and suspected risk factors for breast cancer, including family history,
reproductive and menstrual history, hormone use, alcohol intake and smoking, occupational
history, physical activity, and dietary intake. Women were also asked to report their weight
and height one year before diagnosis (for cases) or reference date (for controls), and at
several times during their life. Anthropometric measurements were taken at the end of the
visit using a standardized protocol and measuring instruments. Body composition (lean and
fat mass, percent body fat) was measured by bioelectrical impedance analysis using a
Tanita® TBF-300A scale. Initially blood sample were obtained from participants, but in
2007, to reduce costs and increase participation, sample collection was restricted to saliva
samples obtained Oragene Kits (DNA Genotek, Inc, Ottawa, ON, Canada).
Among eligible AA women, 75% in NY and 54% in NJ completed an interview and
provided a biologic specimen. As of this writing, 979 AA cases and 958 AA controls have
been enrolled in WCHS phases 1 and 2. We estimate that we will enroll at least 250
additional AA cases each year for the next four years. The study was approved by the
Institutional Review Boards at the University of Medicine and Dentistry of New Jersey,
Mount Sinai School of Medicine, and Roswell Park Cancer Institute and all participants
provide written informed consent before participating in the study.
Black Women’s Health Study (BWHS)
The BWHS is an ongoing prospective follow-up study of health and illness among U.S.
black women, with a focus on cancer.[111] The study began in 1995 when 59,000 AA
women 21–69 years of age from across the United States completed a 14-page postal health
questionnaire. The median age at entry was 38, and participants were residents of 17 states
in mainland U.S.: Northeast, 28%; South, 30%; Midwest, 23%; West, 19%. The baseline
questionnaire elicited information on a wide range of variables, including demographic
factors, use of medical care, family history of breast cancer, reproductive and medical
history, current and past cigarette and alcohol use, current weight and weight at age 18,
height, waist and hip circumference, use of vitamin supplements and medications, diet, and
participation in exercise. Biennial follow-up questionnaires ascertain new cases of breast
cancer and other illnesses and update covariate information. Deaths are identified through
linkage to the National Death Index and by reports from family and friends of participants.
Follow-up is complete for 80% of the baseline cohort after seven follow-up cycles. Medical
record and cancer registry data are sought for all participants who report a diagnosis of
breast cancer. Data are abstracted on year of diagnosis, histology, grade, tumor size, lymph
node involvement, metastases, estrogen receptor status, progesterone receptor status, and
HER-2 neu expression. To date, either medical records or cancer registry data have been
obtained for 1,144 women who reported incident breast cancers; 99% were confirmed as
breast cancer. Eighty-three percent had invasive cancers and 17% carcinoma in situ.
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From 1999–2007, all BWHS participants with known addresses were invited to provide
saliva sample by the mouthwash-swish method.[112] Samples were provided by 26,814
women, for a response rate of 50%. Respondents were somewhat older than non-
respondents, but were similar with regard to geographic region, educational level, BMI, age
at menarche, parity, oral contraceptive use, menopausal hormone use, and family history of
breast cancer. These comparisons indicate that participants with stored samples are highly
representative of all BWHS participants.
The Multiethnic Cohort (MEC) is a prospective cohort study that was designed to provide
prospective data on cancer and other chronic diseases.[113] To maximize the diversity of
exposures, the MEC targeted a range of ethnic groups spanning all socioeconomic levels.
The MEC includes men and women aged 45–75 at recruitment, primarily from five different
racial-ethnic groups, including 16,594 AA women. The cohort was assembled in 1993–1996
by mailing a self-administered, 26-page questionnaire to persons identified primarily
through the driver’s license files for the state of Hawaii and the county of Los Angeles in
California, supplemented with other sources. The baseline questionnaire obtained
information on demographics, medical and reproductive histories, medication use, family
history of various cancers, physical activity and an extensive quantitative food frequency
questionnaire. Follow-up questionnaires were sent in 1999, 2003, and 2010.
Identification of incident breast cancer in study participants is by regular linkage with the
Los Angeles County Cancer Surveillance Program and the State of California Cancer
Registry, both of which are NCI-funded Surveillance, Epidemiology, and End Results
(SEER) registries. Deaths in the cohort are identified by linkage to the state death-certificate
files in CA and with the National Death Index for deaths occurring in other states. Out-
migration in the MEC is low. Based on the extensive tracking of a random sample of the
cohort, the out-migration rate was 3.7% after 7 years of follow-up.
Biospecimen collection in the MEC began in 1996 with the collection of blood and urine
specimens from incident cases of breast, prostate and colorectal cancer, together with a
cross-section of the cohort (N~6,000), for nested case-control studies of genetic
susceptibility and cancer. In the current cycle of the MEC, the effort was expanded and
included the prospective collection of biospecimens (fasting blood, urine, and in a small
subset, buccal cells) from all eligible MEC participants in Hawaii and Los Angeles,
respectively.
METHODS
The AMBER consortium is an NCI-funded Program Project consisting of four cores and
four scientific projects. Core A coordinates administration. Core B includes data collection
in the case-control studies and collection of tumor blocks in CBCS, WCHS, and BWHS.
Core C, the Biospecimen Core, has both a genomics and a pathology component. The
genomics component is responsible for obtaining DNA samples from all studies, preparing
the samples for genotyping, overseeing genotyping of all samples in a single laboratory, and
participating in statistical analyses of the genotype data. In the first year of AMBER,
aliquots of DNA from approximately 3200 breast cancer cases and 3700 controls from
among BWHS, CBCS, and WCHS participants were assembled at Core C, quantified by
pico green and shipped to the Center for Inherited Disease Research (CIDR) laboratory for
genotyping, which began in June 2013. The pathology component of Core C is responsible
for all laboratory activities pertaining to subtyping of breast cancers. TMAs are constructed
at two locations, with CBCS TMAs created at a UNC lab and WCHS and BWHS TMAs
constructed at a Roswell Park Cancer Institute lab. A number of validation studies were
conducted to test the validity and reliability of the immunohistochemistry assays for each
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molecular marker and the “calling” of IHC results. Based on those results, a protocol was
developed such that staining of all samples will be carried out in a single lab at UNC and
scoring of results will be done using the Aperio imaging system. MEC tumor tissue will be
collected and evaluated under separate funding and protocols, with data on subtypes
contributed to AMBER for pooled classifications and analyses.
The Biostatistics and Data Management core, Core D, has responsibility for establishing and
maintaining a database that includes individual-level pathology, genomic, serum biomarker,
and questionnaire data from all four studies. It is also responsible for preparing and
distributing analytic data files and providing biostatistical support for all analyses. Working
closely with the other Cores and scientific investigators, Core D conducts quality control
and cleaning of both genotyping data and questionnaire data.
Variables to be used as main exposures or important covariates were harmonized by Core D
in a two-step process. First, based on a review of all questionnaires, a list of desired
variables was created, with specification of whether a given variable should be provided as
continuous or categorical, and if categorical, specification of the categories. The intent was
to allow investigators from each individual study to carry out cleaning and recoding of their
own data insofar as possible. After receipt of the data, Core D investigators conducted
quality checks and multiple harmonizing recoding in an iterative process with study
investigators to derive common variables that retained as detailed information as possible.
Statistical analyses of questionnaire data
The cohort studies, BWHS and MEC, provided nested case-control data, with up to four
controls randomly selected from among women without breast cancer, matched on year of
birth and on having completed the same questionnaire as the last questionnaire completed by
the case before her diagnosis of breast cancer. The case year of diagnosis was considered to
be the index date for all controls in the same risk set. For time-varying exposure measures,
exposure values were taken from the most recent questionnaire completed before the index
date. The nested case-control data from BWHS and MEC were then pooled with case-
control data from CBCS and WCHS to create an AMBER database for all future analyses.
Associations between exposure variables of interest and specific breast cancer subtypes will
be assessed in the pooled data by calculating odds ratios and 95% confidence intervals using
polytomous logistic regression adjusted for study site, five-year age group, calendar year of
interview , geographic region, years of education, and breast cancer risk factors. In addition,
a random-effects model will be used to estimate combined odds ratios and between-study
heterogeneity with be assessed with Q test statistics.
Case-case analyses will also be carried out. In initial analyses, ER− cases will be compared
with ER+ cases with respect to exposure. After subtyping by the Pathology Core is
complete, each of the other subtypes will be compared with the most common subtype,
luminal A. Case-case analyses will provide additional statistical power because it will be
possible to include cases from CBCS3, for which no controls are available. The validity of
the case-case analyses will be demonstrated by comparing case-control results with case-
case results for the same sets of cases.
Current Status
As shown in Table 1, for the first round of analyses of questionnaire data in the AMBER
collaboration, there are 2,867 ER+ breast cancer cases, 1,480 ER− breast cancer cases, and,
from among the ER− cases, 619 triple-negative cases. A total of 530 breast cancer cases
diagnosed before age 40 are included.
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DNA samples from approximately 3,200 breast cancer cases and 3,700 controls from CBCS,
WCHS, and BWHS are being genotyped in the first round of genotyping; by the time
genotyping is complete and the data are cleaned, pathology data sufficient to classify the
cases by ER and PR status will be available for most of those cases.
PROJECTS AND GOALS
AMBER will integrate data from all levels (molecular to behavioral) to understand breast
cancer risk, with the goal of improvement in health. The first AMBER scientific projects
will focus on the topics addressed in the introduction: associations between breast cancer
subtypes and reproductive risk factors, body size, physical activity, vitamin D and immune/
inflammatory pathways, and genomics. Each of the projects will provide important
information regarding risk factors for breast cancer subgroups. However, the greatest impact
will result from interactions among the projects. The study design for the AMBER
consortium is motivated in large part by the desire to integrate analyses of genome-wide
genetic variation and modifiable epidemiologic risk factors to study gene-environment
interactions.[114] AMBER will forge a link between GWAS results and population-based
epidemiology by integrating findings from the genomics project into the projects that
address modifiable risk factors.
AMBER is the most powerful study, to date, of breast cancer in AA women. With
information on pathologic tumor characteristics in a large set of cases, there will be, for the
first time, adequate statistical power to classify this heterogeneous disease into more
homogeneous subgroups. Using harmonized epidemiological data and biospecimens, it
should be possible to identify modifiable and genetic risk factors for molecular subtypes,
including the most lethal. Our hope is that AMBER will be able to provide definitive
answers to the preponderance of aggressive breast cancer in AA women, paving the way for
prevention initiatives.
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